Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 17, 2017updated 24 Oct 2017 1:25pm

Warp Drive and Roche collaborate to develop new classes of antibiotics

US-based firm Warp Drive Bio has formed a strategic alliance with Roche for the discovery and development of several new classes of antibiotics.

Warp Drive Bio is a drug discovery company focused on the development of therapeutics that exploit the molecules and mechanisms of nature.

The current global health threat of multi-drug-resistant bacterial infections has generated an immediate need for the discovery of new antibiotics with the latest structures and mechanisms of action.

Under the agreement, the company will deploy its proprietary Genome Mining platform to advance multiple new classes of antibiotics with activity against clinically important, drug-resistant, Gram-negative pathogens.

The platform will provide access to natural product drugs that have not been studied previously, owing to historical technology limitations.

Warp Drive Bio CEO Dr Laurence Reid said: “We are committed to bringing urgently needed novel antibiotic medicines to patients, and we are delighted to be collaborating with Roche in that goal.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
“We are committed to bringing urgently needed novel antibiotic medicines to patients, and we are delighted to be collaborating with Roche in that goal.”

“Antimicrobial resistance is an extraordinary threat to global human health, and Warp Drive’s unique platform allows us to access a vast reservoir of uncharacterised natural products from which to identify novel antibiotics.”

As part of the deal, Roche has an option for an exclusive worldwide licence to develop and commercialise certain antibiotic classes that is created as a result of the partnership.

Warp Drive Bio will retain worldwide rights to all other new antibiotic classes from the collaboration.

The company will be eligible to receive up to $300m in payments related to specific clinical, regulatory and sales milestones on products licensed to Roche and up to another $87m in upfront payment, option fees, and milestone payments for preclinical events.

Warp Drive will also receive tiered royalties for development candidates up to double digits on future net sales for products licensed to Roche.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy